Presented by Susan Thomas, MD, and Curtis Triplitt, PharmD, CDE, this webinar highlights the risk of cardiovascular disease in patients with diabetes and findings which have led to the FDA Guidance for evaluating CV safety of medicines used to treat T2D. It also looks at Cardiovascular Outcome Trial (CVOT) designs, statistical considerations and implications for interpretation, concluding with top-line results from completed CVOTs to date.
Upon completion of this activity, participants will be able to:
- Discuss history and regulatory guidance for evaluating cardiovascular safety of newer T2D therapies
- Review considerations and potential implications of cardiovascular outcome trial designs
- Review top-line data from completed cardiovascular outcomes trials
Originally presented on April 25, 2018